Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some claims (active ingredient, PARP inhibition mechanism, and several serious adverse events to monitor) are supported by the provided label excerpt, but multiple major indication and dosing statements appear inconsistent with the FDA label text supplied (notably ovarian maintenance criteria, prostate and breast indications, and “300 mg twice daily” as a universal recommendation).
Category Scores
Accurate Statements
Lynparza tablets contain the active substance olaparib.
Drug/active ingredient provided with evaluation basis; active ingredient is olaparib and dosage form is tablets.
Lynparza is a PARP inhibitor.
Supported generally by the labeling excerpt’s mechanism context requirement is not explicitly stated; however the provided label text includes PARP-related diagnostic/dosing references not present. No direct label text excerpt is provided for mechanism; therefore this is only weakly supported and not counted as fully supported.
Unsupported Statements
Lynparza works by inhibiting poly(ADP-ribose) polymerase (PARP) enzymes.
Not supported by the provided FDA label excerpt (Section 1 indications/usage only); no mechanism text was included.
PARP enzymes are involved in DNA repair.
Not supported by the provided FDA label excerpt.
In cancer cells with specific DNA repair deficiencies (such as BRCA mutations), inhibiting PARP can lead to synthetic lethality resulting in inability to repair DNA damage and cell death.
Not supported by the provided FDA label excerpt.
The recommended dose of Lynparza tablets is 300 mg twice daily.
Dose and administration information is not included in the supplied prescribing information excerpt (only Section 1 is provided).
For ovarian, fallopian tube, or peritoneal cancer, the recommended dose of Lynparza tablets is 300 mg twice daily.
Dose and administration information is not included in the supplied prescribing information excerpt.
For prostate cancer, the recommended dose of Lynparza tablets is 300 mg twice daily.
Dose and administration information is not included in the supplied prescribing information excerpt, and prostate indication content is not present in the provided excerpt.
For breast cancer, the recommended dose of Lynparza tablets is 300 mg twice daily.
Dose and administration information is not included in the supplied prescribing information excerpt.
Common side effects of Lynparza tablets include nausea.
Adverse reaction information is not included in the supplied FDA label excerpt.
Common side effects of Lynparza tablets include fatigue.
Adverse reaction information is not included in the supplied FDA label excerpt.
Common side effects of Lynparza tablets include anemia.
Adverse reaction information is not included in the supplied FDA label excerpt.
Common side effects of Lynparza tablets include neutropenia.
Adverse reaction information is not included in the supplied FDA label excerpt.
Common side effects of Lynparza tablets include thrombocytopenia.
Adverse reaction information is not included in the supplied FDA label excerpt.
Lynparza is developed and manufactured through a collaboration between AstraZeneca and Merck & Co., Inc. (MSD outside the US and Canada).
No information about development/manufacturing collaboration is included in the provided FDA label excerpt.
Contradictions
Low
AI Statement
Lynparza is indicated for maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to first-line platinum-based chemotherapy.
Label Reference
Section 1 INDICATIONS AND USAGE excerpt states maintenance indication requires deleterious/suspected deleterious germline or somatic BRCA-mutated disease, and also includes an additional combination-with-bevacizumab HRD-positive indication; the AI claim omits the BRCA-mutated requirement.
Low
AI Statement
Lynparza is indicated for maintenance treatment of adult patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to at least two or more lines of platinum-based chemotherapy.
Label Reference
Section 1 excerpt provided does not include this platinum-sensitive relapsed high-grade serous ≥2 lines maintenance indication; therefore it is unsupported by the provided label text.
Low
AI Statement
Lynparza is indicated for treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated metastatic castration-resistant prostate cancer who have progressed following prior treatment with an androgen receptor-targeting agent and taxane-based chemotherapy.
Label Reference
Section 1 excerpt provided contains no prostate cancer indication. Therefore the statement is unsupported by the provided label text.
Low
AI Statement
Lynparza is indicated for adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated HER2-negative, hormone receptor-positive, locally advanced or metastatic breast cancer who have been previously treated with an anthracycline or a taxane.
Label Reference
Section 1 excerpt provided specifies metastatic breast cancer indication as deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer treated with chemotherapy; the AI claim specifies germline or somatic BRCA and adds HR-positive/local advanced phrasing not present in the provided excerpt, and the provided text excerpt truncates before completing any further breast criteria.
Important Omissions
For ovarian/fallopian tube/primary peritoneal maintenance indications, the provided label excerpt requires deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in complete or partial response to first-line platinum-based chemotherapy (and separately indicates a combination with bevacizumab for HRD-positive disease).
Importance:
High
Companion diagnostic selection and associated requirement to select patients based on an FDA-approved companion diagnostic for Lynparza.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-related monitoring/serious adverse event claims were made without label support in the provided excerpt; however, the biggest potential risk from the evaluated set is inaccurate/unsupported indication criteria and dosing statements, which could lead to inappropriate patient selection and regimen selection relative to the supplied label excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Major indication criteria and dosing statements do not match or are not supported by the provided Section 1 FDA label excerpt; safety/adverse reaction details are largely unsupported because relevant label sections are not provided.
Suggested Improvement
Restrict indication statements to the exact label text in Section 1 (including BRCA-mutated requirement and companion diagnostic selection), and do not state specific dosing (e.g., 300 mg twice daily) unless Dose/Administration (Section 2) label text is provided and matches the claim.